For the quarter ending 2025-09-30, IRON had $13,327K increase in cash & cash equivalents over the period. -$47,825K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -62,321 | -89,332 |
| Depreciation and amortization | 87 | 105 |
| Stock-based compensation | 9,514 | 14,783 |
| Amortization/accretion of investment securities | 1,739 | 5,148 |
| Loss from initial consolidation of variable interest entity | 0 | -852 |
| Non-cash lease expense | 120 | 229 |
| Non-cash interest expense | 211 | 415 |
| Other non-cash items | 0 | 0 |
| Prepaid expenses and other current assets | -371 | 7,911 |
| Accounts payable | 918 | -1,598 |
| Accrued external research and development expenses | 242 | 322 |
| Other accrued expenses | 4,954 | -2,518 |
| Operating lease liabilities | -156 | 507 |
| Net cash used in operating activities | -47,799 | -89,294 |
| Purchases of marketable securities | 85,436 | 405,876 |
| Maturities of marketable securities | 135,000 | 185,819 |
| Purchases of property and equipment | 26 | 887 |
| Net cash used in investing activities | 49,538 | -220,944 |
| Proceeds from sale of common stock in underwritten offering, net of issuance costs paid | 0 | 234,003 |
| Proceeds from sale of pre-funded warrants in underwritten offering, net of issuance costs paid | 0 | 9,386 |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | 9,766 | 0 |
| Proceeds from stock option exercises | 1,531 | 1,467 |
| Contributions from employee stock purchase plan | 291 | 287 |
| Net cash provided by financing activities | 11,588 | 245,143 |
| Net decrease in cash, cash equivalents and restricted cash | 13,327 | -65,095 |
| Cash and cash equivalents at beginning of period | 192,672 | - |
| Cash and cash equivalents at end of period | 140,904 | - |
Disc Medicine, Inc. (IRON)
Disc Medicine, Inc. (IRON)